A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)
Clinical trial NCT06688240 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06688240
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
- Status
- NOT_YET_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-11-01
- Primary completion
- 2027-07-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.